Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: LY4560736 in Healthy Participants and · Alzheimer's Disease (AD) Recruitment opened Eli Lilly and CompanyPhase 1 NCT07843459
  2. Notable: LY4167586 · Obesity or Overweight With or Without Type 2 Diabetes Recruitment opened Eli Lilly and CompanyPhase 1 NCT07881887
  3. Notable: LY4515100 in Healthy Male Participants Recruitment opened Eli Lilly and CompanyPhase 1 NCT07867327
  4. Notable: LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and · Inflammation (High C-Reactive Protein) Recruitment opened Eli Lilly and CompanyPhase 1 NCT07867340
  5. Notable: Dietary Supplement to Alleviate Dry Mouth Recruitment opened Lacer S.A.Not applicable NCT07847840
  6. Notable: Gastrointestinal Symptoms and Tolerance in Infants Fed Goat or Cow's Milk-based Infant Formula Recruitment opened Ausnutria Hyproca B.V.Not applicable NCT07342972
  7. Notable: CSF Shunt Flow Between "Virtual Off" and "Flow Permissive" Shunt Valve Settings Using a Wireless, Noninvasive Shunt Flow Sensor Recruitment opened Rhaeos, Inc.Not applicable NCT07815314
  8. Notable: JOCOAT Safety and Tolerability Clinical Trial GLAD-04 Recruitment opened ARC Medical Inc.Not applicable NCT07081815
  9. Notable: SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation Recruitment opened Sofwave Medical LTDNot applicable NCT07723664
  10. Notable: Rise & Thrive: Community-Engagement Intervention for Stress and Depression in Youth Sponsor changed: Ann & Robert H Lurie Children's Hospital of Chicago to Seattle Children's Hospital Seattle Children's HospitalNot applicable NCT07554326
  11. Notable: Our Voices Matter: Intervention for Depression in Youth Sponsor changed: Ann & Robert H Lurie Children's Hospital of Chicago to Seattle Children's Hospital Seattle Children's HospitalNot applicable NCT07216326
  12. Notable: Prewarming Duration on Blood Flow After Colon Resection Surgery Recruitment opened Çiğdem Ünal KantekinNot applicable NCT07857538
  13. Notable: Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Recruitment opened Chinese PLA General HospitalPhase 3 NCT07917247
  14. Notable: Cilostazol · Recurrent Stroke Trial Recruitment opened Stanford UniversityPhase 3 NCT07174414
  15. Notable: TAP vs. ESP Blocks for Post-Cesarean Analgesia Recruitment opened Maternity Hospital - State Budgetary Institution of the Rostov Region, TaganrogNot applicable NCT07853482
  16. Notable: Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity Recruitment opened University Health Network, TorontoPhase 2 NCT07515651
  17. Notable: Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills Recruitment opened Qilu Hospital of Shandong UniversityPhase 4 NCT07885462
  18. Notable: SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma Suspended trial terminated Shandong Cancer Hospital and InstitutePhase 2 NCT07274774
  19. Notable: Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) Recruitment opened University of North Carolina, Chapel HillPhase 4 NCT07756359
  20. Notable: Positron Emission Tomography/Computed Tomography (PET/CT) Imaging · a Glioma Recruitment opened Barbara Ann Karmanos Cancer InstitutePhase 2 NCT07735819
  21. Notable: Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Trial status changed: Unknown → Terminated Massachusetts General HospitalPhase 2 NCT05668962
  22. Notable: DOSE-UP · Optimization for Smoking and E-Cigarette Use Pharmacotherapy Recruitment opened Medical University of South CarolinaPhase 2 NCT07754578
  23. Notable: Propranolol Treatment for Postoperative Chylothorax Recruitment resumed after suspension June WuPhase 1/2 NCT06833320
  24. Notable: Addition of OK-1 Weekly Paclitaxel · Endometrial Cancer Recruitment opened University of OklahomaPhase 2 NCT07737795
  25. Notable: Diagnostic Performance of ACP3-Targeted PET Imaging · Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study Recruitment opened Yong HePhase 2 NCT07830212